Filing Flows › Interpace Biosciences (IDXG) › Net income
Interpace Biosciences (IDXG) net income by quarter
Interpace Biosciences' net income was $158K in Q2 2026 (second quarter 2026), -78% from Q1 2026. Over the last 6 quarters it ranged from $158K (Q2 2026) to $22.7M (Q4 2025).
| Quarter | Net income | Q/Q | Y/Y |
|---|---|---|---|
| Q2 2026 | $158K | -78% | — |
| Q1 2026 | $721K | -97% | -56% |
| Q4 2025 | $22.7M | 25× | 12× |
| Q3 2025 | $911K | -45% | — |
| Q1 2025 | $1.6M | -12% | — |
| Q4 2024 | $1.9M | — | — |
Q2 2026 at a glance
Interpace Biosciences, Q2 2026: revenue $9.1M (-1% year over year), operating margin 3.5%, net earnings $158K, operating cash flow $98K. The chart follows the revenue to costs, profit and cash.
Questions
What is Interpace Biosciences' net income?
Interpace Biosciences' net income was $158K in Q2 2026 (second quarter 2026), -78% from Q1 2026.
How has Interpace Biosciences' net income changed?
Over the last 6 quarters it ranged from $158K (Q2 2026) to $22.7M (Q4 2025).